HBSP (USA)
-
Godiva Japan: Think Local, Scale Global
Deshpande, Rohit; Cekin, Esel; Kanno, AkikoCase HBS-517056-EMarketingThis case tracks Jerome Chouchan's strategies and execution for a successful turn around of Godiva Japan's operations which was experiencing a decline in sales when he became the managing director of the company in 2010. Through various initiatives and innovations, Godiva Japan had targeted a variety of demographic segments in different sales points, acquired new customers and created a moment of luxurious consumption for all ages. Accordingly, w...Starting at €8.20
-
The Abraaj Group and the Acibadem Healthcare Investment (A)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214021-EFinanceThis case concerns the proposed buyout of Acibadem, a leading hospital chain in Turkey. Abraaj, a MENA region private equity firm, proposes to make its first investment in Turkey. The case highlights the role of Turkish health care reform in driving the value. The case provides an opportunity to estimate the potential return on investment as well as evaluate the structuring of the transaction.Starting at €8.20
-
The Dubai International Film Festival, Teaching Note
Deshpande, Rohit; Schwalb, NathanielTeaching Note HBS-519084-EMarketingTeaching note for case 517110.Starting at €0.00
-
Rebranding Godiva: The Yildiz Strategy
Deshpande, Rohit; Cekin, EselCase HBS-515059-EMarketingThis case concerns Yildiz Holding's acquisition of Godiva Chocolatier from its previous owner, Campbell Soup, and its strategy in preserving Godiva's "made in Belgium" brand position. Provenance Paradox, a problem faced by companies in emerging countries trying to establish their brands in developed markets, had not become a problem for Yildiz Holding. After patiently waiting five years and seeing the company not performing as desired, Murat lk...Starting at €8.20
-
The Abraaj Group and the Acibadem Healthcare Investment (B)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214022-EFinanceThis case provides an update on the ultimate outcome of the transaction presented in The Abraaj Group and the Acibadem Healthcare Investment (A).Starting at €5.74